CHMP recommends Leo Pharma's tralokinumab for approval in atopic dermatitis

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Leo Pharma's new eczema treatment tralokinumab within the EU. There is hope the drug will take the company to new heights.

Photo: Leo Pharma / PR

Almost five years after acquiring tralokinumab from Astrazeneca, Leo Pharma is at the cusp of getting approval for the drug on the European market.

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation of the drug, which more or less ensures a final approval. Now, all tralokinumab needs is a formal authorization from the EU Commission, which usually arrives after a couple of months.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs